Introduction
============

Several cancers such as melanoma, breast and prostate cancer are known to spread through the lymphatic system [@B1]. Sentinel lymph nodes (SLN) are described as the first nodes to receive lymphatic drainage from a tumour and sentinel lymph node biopsy (SLNB) involves the identification of SLNs for removal and histopathological analysis to evaluate the presence or absence of metastases. Based on this information, clinicians decide whether or not further surgery is indicated. Surgical removal of metastatic SLNs and SLNB can improve disease-free interval and increase survival rate [@B2],[@B3]. However, \>70% of excised SLNs in breast cancer or melanoma have been found to be negative/healthy SLNs, exposing these patients to unnecessary surgery and post-operative risks such as lymphoedema, seroma formation and nerve or vessel damage [@B4]. Thus, a non-invasive preoperative imaging method of locating and discriminating between metastatic and healthy SLNs would be an important tool to avoid unnecessary biopsies and improve guidance for SLNB~.~

Several clinical imaging methods are available for the detection of SLNs. Ultrasound and computed tomography (CT) have been used to find enlarged SLNs, but size is not a suitable indicator for metastasis [@B5]. ^99m^Tc-nanocolloid mixed with a blue/fluorescent dye can be used for SLN imaging by lymphoscintigraphy or single-photon emission computed tomography (SPECT) [@B6]. However, these imaging techniques only locate SLNs, and do not detect the presence of metastasis. \[^18^F\]FDG positron emission tomography (PET) is useful to identify macrometastases but not micrometastases (size between 0.2 - 2 mm) and it may be difficult to locate metastases in LNs in close proximity to areas of high \[^18^F\]FDG uptake [@B7]. Dynamic \[^18^F\]FDG PET-lymphography is a recent promising technique where the radiotracer is injected subcutaneously, and has been shown to be efficient at locating and characterizing SLNs but lacks sensitivity in differentiating acute inflammatory lymphadenopathy from metastatic LNs [@B8]. Photoacoustic imaging has also shown promise for detecting LN micrometastases in melanoma [@B9],[@B10].

MRI has excellent spatial resolution and, in combination with superparamagnetic iron oxide nanoparticles (SPIOs), is capable of detecting micrometastases in the clinical setting at very low SPIO concentrations [@B11],[@B12]. SPIOs are taken up by macrophages where they accumulate creating negative contrast (low signal intensity in T2/T2\* weighted MRI) in the healthy tissue of SLNs, but not in metastatic LN tissue that lacks high concentrations of macrophages [@B4]. This property has resulted in the identification of contrast patterns of SLN uptake for metastatic and non-metastatic nodes [@B13]. The low sensitivity of MRI, however, makes whole-body identification of SPIO biodistribution and SLN localisation challenging, which is an important consideration in cancers with distant SLNs and/or variable location of the primary tumour, such as melanoma [@B14].

One approach to overcome this limitation of SPIO-MRI is to combine the full-body imaging capabilities and sensitivity of PET with the ability of SPIO-MRI to identify SLN metastases using radiolabelled SPIOs. This approach would allow the use of PET for both sensitive whole-body SLN localisation and also guiding high resolution MRI for evaluating intra-LN SPIO distribution. Several groups, including ours, have previously demonstrated the concept of SLN localisation with radiolabelled SPIOs using nuclear-MR imaging; however, to the best of our knowledge, none have demonstrated localisation and characterisation in a metastatic animal cancer model [@B15]-[@B28]. The aim of this work was to develop a clinically translatable ^68^Ga-labelled PET-MR SLN imaging agent based on a CE-approved SPIO for SLN localisation (Sienna+). To evaluate its potential in a relevant metastatic mouse cancer model, we chose a reporter gene (human sodium iodide symporter - hNIS) expressing breast cancer mouse model that develops spontaneous axillary lymph node metastases and allows the use of SPECT imaging with ^99m^TcO~4~^-^ (hNIS substrate) to confirm the health status of SLNs prior to ^68^Ga-Sienna+ PET-MRI (Scheme [1](#SC1){ref-type="fig"}).

Materials and Methods
=====================

Radiolabelling of Sienna+ with ^68^Ga
-------------------------------------

Sienna+ SPIO nanoparticles with carboxydextran coating (26-30 mg Fe/mL, Z-average diameter 59 ± 0.7 nm; pH = 5.0-7.0; sterile) were purchased from Endomag (Cambridge, UK). ^68^Ga *(t~1/2~* = 68 min, β^+^ = 89%) was eluted from a ^68^Ge/^68^Ga-generator (Eckert & Ziegler, Germany) with 5 mL of 0.1 M HCl for high performance capillary electrophoresis (HPCE) (Fluka, USA). The pH of the gallium elution (400 µL) was adjusted to 5 with 4 M ammonium acetate solution (40 µL, 160 µmol, Sigma-Aldrich, UK), Sienna+ (67 µL, 2 mg Fe) was then added and the mixture reacted in a sealed 1.5 mL plastic microcentrifuge tube at 100 °C for 10 min. The reaction solution was filtered (sterile hydrophilic Millex-LG 13 mm 0.2 µm PTFE, Merck, Germany). The pH of the final product was \~6. Radiolabelling using GMP protocol: A CE-approved sterile vial of Sienna+ (2 mL, 60 mg Fe) was injected with 100 µL of the pH-adjusted ^68^Ga elution (pH 5) using sterile techniques with a 1 mL syringe and filter (same as above). The vial was incubated at 100 °C for 10 min. After cooling, the radiochemical purity of ^68^Ga-Sienna+ was measured using TLC (F-254 silica gel 60 plates, Merck) with citrate buffer (pH 5) as an eluent (0.1 M tri-sodium citrate dihydrate (Sigma-Aldrich) and 0.1 M citric acid monohydrate (Fisher Scientific, UK)) and analysed by autoradiography. Exposed phosphor screens (PerkinElmer, USA) were scanned with a Cyclone Plus system (PerkinElmer). The percentage of ^68^Ga-Sienna+ and free ^68^Ga were calculated by region of interest (ROI) analysis using OptiQuant 5.0 software (PerkinElmer). Nanoparticle hydrodynamic size was measured by dynamic light scattering (DLS) and the effective electric charge of the surface by zeta potential measurements in a Zetasizer Nano ZS instrument (Malvern Instruments Ltd, UK) in deionised water (size) or 10% PBS (zeta potential).

*In vitro* serum stability
--------------------------

^68^Ga-Sienna+ (100 µL, 10 MBq, 0.3 mg Fe) was mixed with human serum (900 µL, Sigma-Aldrich) and the mixture incubated at 37 °C for 4 h. Samples (200 µL) were collected every hour and analysed by size-exclusion chromatography with a Superose 6 Increase 10/300 GL column (GE Healthcare, UK) connected to an Äkta system (GE Healthcare) using a 0.5 mL/min flow of PBS as eluent. Samples of 1 mL were collected and measured in a gamma counter (LKB Wallac, Finland). ^68^Ga-Sienna+ eluted at 8-15 mL and serum-bound/free ^68^Ga at 20-25 mL. Serum stability was expressed as percentage of ^68^Ga-Sienna+ in serum (as calculated from size-exclusion chromatography) over time.

Cell culture and *in vitro* uptake studies
------------------------------------------

Rat breast adenocarcinoma cells MTLn3E Δ34-CXCR4-GFP hNISTagRFP (3E.Δ.NT) were generated and characterised as previously described [@B29]. Mouse monocyte macrophages J774A.1 were a gift from Dr. Varsha Kanabar at the Institute of Pharmaceutical Sciences in King\'s College London. Generation and characterisation of mouse leukaemic monocyte macrophage RAW264.7.GFP cells are described in the [supplemental information](#SM0){ref-type="supplementary-material"}. All cell lines were maintained in an atmosphere of 5% CO~2~/95% air. All cell culture reagents were obtained from Sigma-Aldrich. 3E.Δ.NT cells were cultured in MEM eagle with alpha modification supplemented with 5% FBS, 100 IU penicillin-streptomycin, 0.5 mg/mL G 418 disulfate salt and 0.5 µg/mL puromycin. Macrophage cell lines were cultured in DMEM high glucose medium supplemented with 10% FBS and 1 mM sodium pyruvate. All cell media were supplemented with 2 mM L-glutamine.

For cell uptake studies of ^68^Ga-Sienna+, each cell line was cultured on 6-well plates 24 h before the experiment using 1 million cells/well. The medium was then removed and 1 mL of ^68^Ga-Sienna+ solution in complete medium was added (600 kBq/mL, 5.3 µg iron/mL). Cells were incubated for 1, 2 or 3 h. The supernatant was collected and cells washed twice with PBS. 3E.Δ.NT cells were collected by trypsination. Macrophages were collected by scraping. The radioactivity of the samples (cell pellet, supernatant and washings) was measured in a gamma counter to allow us to calculate cell uptake, expressed as a percentage of total radioactivity per million cells.

Animal experiments
------------------

Animal experiments were approved by the King\'s College London Animal Welfare and Ethical Review Body (AWERB) and were in agreement with UK Home Office regulations. Female 5-6 weeks old NOD scid gamma (NSG) (NOD.Cg-*Prkdc^scid^ Il2rg^tm1Wjl^/*SsJ, n = 6) and B6CBAF1 mice were obtained from Charles River (UK). Mice were housed within filter-top cages at least 5 days before starting the experiments and given food and water *ad libitum*. For tumour inoculation, 3E.Δ.NT cells (1 × 10^6^ cells in 50 µL of PBS) were injected subcutaneously into the left mammary fat pad between the fourth and fifth nipple in the NSG mice. Once tumours were palpable, their volume was monitored using calipers. During tumour inoculation and imaging procedures, mice were anaesthetised with isoflurane (Vet Tech Solutions Ltd., UK), 3% in oxygen for induction and 1.5-2% for maintenance.

SPECT-CT and PET-CT imaging
---------------------------

On day 19 or 20 after inoculation, NSG mice were scanned with SPECT-CT using ^99m^Tc-pertechnetate (^99m^TcO~4~^-^) to confirm metastasis of left axillary SLNs. ^99m^TcO~4~^-^ was eluted from a Drytec generator (GE Healthcare) using saline. ^99m^TcO~4~^-^ (100 µL, 31 ± 3 MBq) was injected intravenously into the tail vein. After 40 min, a 30 min scan was acquired on a NanoSPECT-CT Silver Upgrade (Mediso, Hungary) with 1 mm collimators, 45 s/frame. CT was obtained with 55 kVp tube voltage, 1000 ms exposure time and 180 projections.

A healthy B6CBAF1 mouse was used to find the optimal time point for a PET scan after ^68^Ga-Sienna+ injection (20 µL, 2.2 ± 0.9 MBq, 79 µg Fe) subcutaneously into left front paw. A scan was acquired for 2.5 h on a nanoScan PET-CT preclinical scanner (Mediso) 20 min after injection. CT was obtained with a 45 KVp tube voltage, 600 ms exposure time and 180 projections.

For the tumour/SLN metastasis study NSG mice were imaged by PET-CT on day 21/22 after inoculations. ^68^Ga-Sienna+ (20 µL, 2.2 ± 0.9 MBq, 79 µg Fe) was injected subcutaneously into both left and right front paws. After 1 h, a 30 min scan was acquired. SPECT-CT images were reconstructed in a 128 × 128 matrix using HiSPECT (Sci-vis GmbH, Germany) software package, and images fused using Bioscan InVivoScope (Bioscan, USA) software. PET-CT data were reconstructed using a Monte Carlo based full 3D iterative algorithm (Tera-Tomo, Mediso). Data were corrected for attenuation and scatter, and decay correction for the time of injection was applied. A total of 4 iterations and 6 subsets were applied. SPECT-CT Images were reconstructed with a voxel size of 0.16 x 0.16 x 0.16 mm and PET scans with a voxel size of 0.21 x 0.21 × 0.21 mm. Images were analysed using VivoQuant 2.50 software (Invicro LLC., USA) by drawing ROIs and calculating %ID/mL values.

MR imaging
----------

MR imaging was performed 6 h after ^68^Ga-Sienna+ injection using a 3T Philips Achieva MR scanner (Philips Healthcare, The Netherlands) equipped with a clinical gradient system (30 mTm^-1^, 200 mT/m/ms) and a single-loop surface coil (diameter = 47 mm). Mice were anesthetised and placed on the coil in a prone position. After scout scans, a coronal 3D turbo spin echo T2-weighted scan (TR = 500 ms, TE = 61 ms, flip angle = 90°, FOV = 40 x 30 x 12 mm^3^, acquired matrix 200 x 148, slice thickness = 0.5 mm, resolution = 0.2 x 0.2 mm, slice number = 24, averages = 2, acceleration factor = 10, scan duration = 8 min 49.5 s) and a transverse 3D turbo spin echo T2-weighted scan were acquired (TR = 500 ms, TE = 47 ms, flip angle = 90°, FOV = 31 x 31 x 8 mm, acquired matrix 80 x 74, slice thickness = 0.5 mm, resolution = 0.4 x 0.4 mm, slice number = 16, averages = 4, acceleration factor = 10, scan duration = 6 min 1.5 s). Finally, coronal 3D T2 maps were acquired with a turbo spin echo sequence (TR = 500 ms, TE = 21 ms, echo spacing = 28 ms, 5 echoes, flip angle = 90°, FOV = 25 x 25 x 12 mm, acquired matrix 124 x 124, slice thickness = 0.5 mm, resolution = 0.2 x 0.2 mm, slice number = 24, averages = 1, acceleration factor = 10, scan duration = 18 min 32.5 s) and coronal 3D T2\* maps with a turbo gradient echo sequence (TR = 44 ms, TE = 4.7 ms, echo spacing = 5.0 ms, 8 echoes, flip angle = 25°, FOV = 25 x 25 x 12 mm, acquired matrix 124 x 124, slice thickness = 0.5 mm, resolution = 0.2 x 0.2 mm, slice number = 24, averages = 4, acceleration factor = 1, scan duration = 19 min 57.5 s).

MR scans were analysed using OsiriX Lite software (Pixmeo SARL, Switzerland) and ROIs were drawn manually around the axillary LNs on the T2 and T2\* images. The ROI was drawn on the first image and then propagated to the rest of the echoes. Signal intensities of 3 consecutive slices containing the LNs were averaged and plotted against echo times. Exponential decay was fitted in GraphPad Prism 7 (USA) using a one-phase decay. Spin-spin relaxation time T2 (ms) was calculated as 1/-K, K being the rate constant, and relaxation rate R2 (s^-1^) as 1/T2x1000. T2\* and R2\* were calculated the same way.

Histology
---------

Mice were terminated after MR scans and fluorescence photographs were taken using a Nikon D5200 camera (Japan) and a Nikon DX AF-S NIKKOR 18-55nn 1:3.5-5.6G ED II lens connected to an appropriate emission filter (SFA-LFS-RB, Nightsea, USA) using filter goggles and a fluorescent torch (emission 500 nm). Axillary LNs (metastatic and non-metastatic) were collected for histological analysis. LNs were fixed in 10% neutral buffered formalin (Pioneer Research Chemicals Ltd., UK) for a minimum of 2 days. LNs were processed into paraffin blocks using the Leica Biosystems tissue processor (Germany). Tissues were dehydrated through 70% EtOH 1.5 h, 100 % EtOH 5 h, xylene 3 h and paraffin wax 3 h. Nodes were cut into 5 µm sections and mounted on superfrost plus slides (VWR, USA). Immunohistochemistry staining was performed in the Ventana Discovery XT instrument (Ventana Medical Systems, USA), using the Ventana DAB Map detection Kit. Cancer cells were detected by GFP staining. Sections were pre-treated with EDTA buffer (45 min, Ventana cell condition 1 solution) before incubation in a primary antibody solution (1:5000 ab290 8 h, Abcam, UK) and secondary swine anti-rabbit antibody (1:200 E0353 32 min, Dako, USA). Macrophages were stained with Iba1 antibody (1:250, 4 h, Wako Chemicals GmbH, Germany) in the same way as in GFP staining, except that slides were incubated in the secondary antibody solution for 1 h. All slides were haematoxylin counterstained according to automatic protocol. Iron staining was performed with Perls Prussian blue protocol: sections were brought to distilled water and flooded with equal parts mixture of 2% ferrocyanide (VWR) and 2% hydrochloric acid (VWR) for 10 min. Slides were washed with water and counterstained with 0.1% neutral red stain (Acros Organics, Belgium) for 1 min. Slides were rinsed with water and dehydrated in absolute alcohol. Slides were digitised using the Leica SCN400F scanner with 40x magnification.

Statistical analysis
--------------------

Statistical significances (*P* \< 0.05) in the cell uptake studies were calculated by one-way ANOVA with Bonferroni correction and otherwise by two-tailed independent samples Student\'s t-test using IBM SPSS Statistics 24 software (USA).

Results
=======

^68^Ga-radiolabelling of Sienna+
--------------------------------

Sienna+ was radiolabelled with ^68^Ga without using a chelator (Figure [1](#F1){ref-type="fig"}a). The reaction was optimised by testing the effect of pH (4, 5 and 6, before adding Sienna+) and temperature (40, 80 and 100 °C) using a 10 min reaction time (Figure [1](#F1){ref-type="fig"}c). Analysis of the reaction conversion was performed by radio-TLC. The majority (\>95%) of free ^68^Ga eluted with the solvent front, whereas ^68^Ga-Sienna+ stayed at the origin (Figure [1](#F1){ref-type="fig"}b). Increasing temperature and pH increased radiolabelling conversion (Figure [1](#F1){ref-type="fig"}c). Highest conversion of ^68^Ga-Sienna+ was obtained at 100 °C at pH 6 in 10 min reaction time (Figure [1](#F1){ref-type="fig"}d). DLS measurements, however, showed aggregation at these conditions (data not shown, hydrodynamic size \>100 nm). Therefore, for the *in vitro/vivo* experiments, Sienna+ was radiolabelled at pH 5 and 100 °C in 10 min yielding ^68^Ga-Sienna+ with 93 ± 0.8 % radiochemical purity (RCP) and in 78 ± 1.4 % radiochemical yield (RCY) (low RCY due to loss of material during the sterile filtration step). The maximum specific activity (A~s~ ) obtained was 67 MBq/mg of Fe (non-optimised and non-decay corrected). Hydrodynamic size was slightly higher and zeta potential lower than for unlabelled Sienna+ (Table [1](#T1){ref-type="table"}). However, when the entire contents of the vial were labelled (using GMP-radiolabelling protocols), RCP and RCY \>93% were obtained and no changes in hydrodynamic size/zeta potential were observed (Figure [1](#F1){ref-type="fig"}e, Table [1](#T1){ref-type="table"}).

*In vitro* serum stability and cell uptake studies
--------------------------------------------------

^68^Ga-Sienna+ in human serum at 37 °C showed good radiolabelling stability for at least up to 4 h (84 ± 6 %, Figure [2](#F2){ref-type="fig"}a). The cell uptake study of ^68^Ga-Sienna+ was performed in the same breast cancer cell line as used in the *in vivo* study (3E.Δ.NT) and with two different macrophage cell lines (J774A.1 and RAW264.7.GFP). In all the cell lines tested, ^68^Ga-Sienna+ uptake increased over time (Figure [2](#F2){ref-type="fig"}b). Both macrophage cell lines had significantly higher uptake than cancer cells at all time points (*P* \< 0.001). Highest uptake (12 ± 1%) was found in J774A.1 cells at 3 h, compared to 2.0 ± 0.1% in cancer cells.

*In vivo* imaging and histology
-------------------------------

Six NSG mice were inoculated with 1×10^6^ 3E.Δ.NT breast cancer cells into the left mammary fat pad. After 3 weeks, the primary tumour metastasised into the left axillary lymph nodes (LALNs), as assessed by ^99m^TcO~4~^-^ SPECT (Figures [3](#F3){ref-type="fig"}a-b). ^99m^TcO~4~^-^ is a substrate for hNIS, which is expressed by the cancer cells [@B30]. Using this method, metastasis in all LALNs could be confirmed. Metastasis was also observed in the lungs (Figure [3](#F3){ref-type="fig"}b). Organs that endogenously express NIS were also visible (stomach, salivary glands, thyroid and mammary glands) (Figures [3](#F3){ref-type="fig"}a-b). 3E.Δ.NT cells also express green fluorescent protein (GFP), allowing visual identification and confirmation of LALN metastasis by fluorescence detection during dissection (Figure [3](#F3){ref-type="fig"}f) and by GFP staining during histological analysis (*vide infra*). In one mouse metastasis was also found in the right axillary lymph node (RALN). In another mouse the health status of the RALN could not be confirmed and was excluded from the analysis. Therefore, in the final analysis, seven metastatic and four healthy LNs were included.

Prior kinetic studies in tumour-bearing mice demonstrated slow SPIO draining (*ca.* 24h) into the axillary SLN when peri/intratumoural injections were used, which would prevent imaging using ^68^Ga. In clinical studies, Sienna+ has shown fast SLN accumulation (\<1h); for this reason we evaluated paw injections, a well-proven route of administration of nanoparticulates that results in fast axillary LN accumulation. ^68^Ga-Sienna+ SLN uptake kinetics via paw injection were first assessed in a B6CBAF1 mouse. There was a fast uptake in axillary LN within 20-50 mins that did not considerably change for up to 170 min (data not shown). Therefore, in the 3E.Δ.NT/NSG model, PET scans were performed 1 h after injection of ^68^Ga-Sienna+ into both front paws. MRI was performed 6 h post injection due to the logistics of these experiments. PET imaging showed accumulation of ^68^Ga-Sienna+ in healthy axillary LNs (SLN~health~), as well as - although at a significantly lower uptake level - healthy brachial LNs (Figure [3](#F3){ref-type="fig"}c and [3](#F3){ref-type="fig"}e). The high uptake in SLN~health~ allows for differentiation from SLN~met~, which had only background uptake (Figure [3](#F3){ref-type="fig"}c). Image-based quantification demonstrated a significantly higher uptake in axillary SLN~health~ compared to SLN~met~ (2.2 ± 0.9 *vs.* 1.1 ± 0.2 %ID/mL, *P* = 0.006; Figure [3](#F3){ref-type="fig"}g). It should be noted that the %ID/mL values for SLN~health~ are likely to be an underestimation of the real value. This is due to their small size that prevented accurate segmentation by CT and the substantial partial volume effect from the PET signal that was used for measuring their volume. ^68^Ga-Sienna+ was also found in the liver (5.3 ± 1.2 %ID/mL), heart (2.1 ± 0.3 %ID/mL), lungs (1.2 ± 0.3 %ID/mL) and bladder (1.5 ± 0.4 %ID/mL) (Figure [3](#F3){ref-type="fig"}e). In other organs, uptake was below 1 %ID/mL. Most of the injected ^68^Ga-Sienna+ remained in the injection site at the time of the PET scan (67 ± 14 %ID/mL). *Ex vivo* biodistribution studies were not possible due to the timing of the imaging experiments (MRI was performed 6 h after PET imaging), which resulted in decay of the radionuclide.

MRI identified metastasis in SLNs that could not be identified by preclinical PET (Figure [4](#F4){ref-type="fig"}). SLN~met~ were identifiable in MRI due to their large size and high signal intensity in T2-weighted images due to the absence of ^68^Ga-Sienna+ (Figures [3](#F3){ref-type="fig"}d and [4](#F4){ref-type="fig"}). Quantification of the MR images demonstrated these differences with SLN~health~ having significantly lower (T2\*)/higher (R2\*) values than SLN~met~ (Figure [3](#F3){ref-type="fig"}h). T2 and R2 were not significantly different between SLN~health~ and SLN~met~, as expected due to the higher sensitivity of T2\*-weighted sequences for iron contrast compared to T2-weighted MRI [@B31].

SLNs from the imaging study with different levels of metastasis and therefore macrophage density were analysed by histology using GFP staining (3E.Δ.NT cells), Iba1 (macrophages) and Perl\'s Prussian blue (iron/Sienna+) (Figure [4](#F4){ref-type="fig"}). The location and density of the GFP stain was inversely correlated with that of the macrophage/iron stain and the macrophage-rich areas directly correlated to the iron stain. SLN~met~ were positive for GFP stain whereas healthy SLNs were negative (It should be noted here that there was weak non-specific binding of the GFP stain to SLN~health~, despite absence of GFP-expressing 3E.Δ.NT cancer cells as confirmed by lack of fluorescence). One metastatic SLN~met~ showed a concentrated localization of macrophages and Sienna+ whereas fully metastatic SLN~met~ presented a disperse distribution and low density of macrophages and absence of Sienna+. SLN~health~ showed a high density and co-localization of both macrophages and Sienna+.

Discussion
==========

The aim of this study was to synthesise and evaluate the potential of ^68^Ga-Sienna+ for locating and characterizing the health status of SLNs with PET-MRI. Sienna+ is a clinically approved SPIO and CE-marked device used in several clinical trials in conjunction with a magnetometer for intrasurgical SLN guidance [@B32].^68^Ga was chosen due to its availability from a GMP-grade generator, its short half-life ideal for SLN imaging, and the possibility of using a chelate-free approach that allows for simple GMP compatible radiolabelling [@B33]-[@B35]. Sienna+ nanoparticles were labelled with ^68^Ga without a chelator in a fast and efficient way. A temperature of ≥80 °C was found to be required for efficient labelling. Lower temperatures (40 °C) resulted in RCY below 55%, independently of pH. At high temperatures (100°C) and pH ≥ 6 aggregation occurred. This was prevented by performing the reaction at pH 5. For animal experiments the nanoparticle solution had to be concentrated due to the small volume required for injection (20 µL). This caused a slight increase in the average hydrodynamic particle size, most likely due to minor aggregation as a result of the higher concentration (Table [1](#T1){ref-type="table"}). This slight size increase is not expected to result in any significant changes to the pharmacokinetics/biodistribution of Sienna+. Furthermore, when the entire contents of the vial of Sienna+ (2 mL) were radiolabelled (GMP-protocol) the physicochemical properties of the nanoparticle (hydrodynamic size and zeta potential) remained unchanged (Table [1](#T1){ref-type="table"}). The highest specific activity achieved in our studies (A~s~ = 67 MBq/mg of Fe) would theoretically allow preparation of up to 4 GBq of ^68^Ga per vial (each vial contains *ca.* 60 mg Fe).

The RCP achieved was within the limits of the European Pharmacopoeia for ^68^Ga radiotracers such as \[^68^Ga\]Ga-DOTATOC (≥91% RCP) [@B36], making purification from free ^68^Ga unnecessary. It is not known where exactly ^68^Ga binds to Sienna+, to the coating or the magnetite core. Previous reports using this radiolabelling method, however, suggest radiometal binding to the magnetite core [@B33]. ^68^Ga-Sienna+ was sufficiently stable in serum, with 84 ± 6 % of ^68^Ga-Sienna+ intact after 4h incubation. It should be noted that when used *in vivo,* Sienna+ is injected subcutaneously, and not intravenously. Furthermore, human studies with Sienna+ report fast lymph node uptake, as early as 20 min post injection [@B37].

As expected from the avidity of dextran-coated SPIOs for macrophages, the *in vitro* cell uptake studies were in agreement with the *in vivo* PET-MRI study, showing a significantly higher uptake of ^68^Ga-Sienna+ in macrophages/SLN~health~ compared to cancer cells/SLN~met~ (Figures [2](#F2){ref-type="fig"}-[3](#F3){ref-type="fig"}) [@B38]. These findings were confirmed by histology. PET allowed sensitive detection of healthy SLNs (Figure [3](#F3){ref-type="fig"}e). MRI, on the other hand, allowed the identification of their health status (Figure [3](#F3){ref-type="fig"}d). Having the complementary information from both PET and MRI and using a bimodal agent allows highly sensitive localization and characterization of SLN and their status at the whole-body level. It is important to mention that, in our preclinical study, partial metastasis could only be detected by MRI by low signal intensity areas (healthy LN tissue) within high signal intensity SLNs (metastatic LN tissue) (Figure [4](#F4){ref-type="fig"}) whereas by PET these SLNs did not show any measurable signal due to the highly localised \[^68^Ga\]Ga-Sienna+/macrophage density that is below the spatial resolution limits of preclinical PET due to the partial volume effect. The larger size of human lymph nodes should allow the detection of partial metastasis by both PET and MRI. A likely drawback for the clinical use of ^68^Ga-Sienna+ PET-MRI is that fully metastatic lymph nodes, which do not take up radiolabelled SPIOs, may remain undetected. This could potentially be overcome by the inclusion of diffusion weighted (DW)-MRI into the protocol, which does not depend, but can benefit, from SPIO contrast [@B39],[@B40].

Looking into how ^68^Ga-Sienna+ could be used for clinical LN imaging, we envisage that after subcutaneous injection of ^68^Ga-Sienna+, in the same way as ^99m^Tc colloids and Sienna+ are currently used for SLNB, patients could undergo a PET-MRI examination where PET will be used first to identify the location of SLN~health~ and partially-metastatic SLN~met~, and second to guide high resolution MRI to these areas for characterization of their health status. This MR step could include DW-MRI in addition to T2/T2\*-weighted sequences to identify fully metastatic SLN~met~. One challenge to overcome in order to provide confidence to the use of preoperative SPIO-MRI as a substitute for *ex vivo* histology will be to prevent false positives and negatives. Studies to date using SPIO-MRI in patients have shown a very low number of false-positives (and mostly due to the presence of fatty hilum)[@B41]. Hence it seems that a more challenging problem will be to prevent false negatives, particularly those involving micrometastases. Indeed, human studies thus far have allowed the detection of LN micrometastases of *ca*. 2mm, and a non-optimal number of false-negatives (*e.g*. 40% of false negatives later identified as micrometastases by histology [@B41]). Several challenges should be overcome to improve this. First, current clinical SPIO/MRI technology does not allow the detection of smaller lesions due to its inherent spatial resolution limitations (potentially sub-millimetre, but restricted by scan time limitations, patient movement and other factors). The second challenge is that the presence of SPIO-related signal in the healthy portion of LNs may obscure small metastatic lesions. To improve this, complementary imaging tests using higher spatial resolution techniques such as photoacoustic imaging [@B9], and/or improvements in MRI technology (high-resolution 7T magnets, improved coils/sequences for SLN SPIO imaging) or SPIO design (improved relaxation properties and doses), may be able to address these limitations in the future. After imaging, ^68^Ga-Sienna+ could then be detected visually during surgery (or using the standard gamma-probes if ^68^Ga is still detectable) or with the help of a handheld magnetometer, even days after injection [@B42].

Conclusion
==========

With the aim of developing a preoperative PET-MRI method to inform sentinel lymph node biopsies (SLNB), we have radiolabelled a clinically-approved SPIO for sentinel lymph node localization (Sienna+) with ^68^Ga using a GMP-compatible, chelate-free method. *In vitro* and *in vivo* studies were performed to confirm the ability of ^68^Ga-Sienna+ in combination with PET-MRI, to locate and characterise SLNs using a breast cancer mouse model that develops spontaneous lymph node metastases. ^68^Ga-Sienna+ uptake levels in SLNs, as measured by PET-MRI followed by histological confirmation, correlate with the level of metastasis/macrophage density. Thus, we have provided proof of concept that ^68^Ga-Sienna+ PET-MRI could be a useful preoperative imaging tool for informing SLNB procedures by allowing the localization at the whole body level (using PET) and characterization (using PET and MRI) of local and distant SLNs from a single imaging session. This would be particularly useful in cancers where the location of the primary tumour, and hence lymphatic drainage, is variable (*e.g.* melanoma). One particular challenge for clinical translation will be the avoidance of false negatives/positives, and it is expected that improvements in MRI/SPIO technology may be able to address this. In future clinical studies, bigger sample sizes and blinded evaluation would be required to confirm the absence of false negatives/positives and to determine cut-off values for image-based quantification and intralymphatic SPIO distribution that would allow accurate prediction of SLN health status in patients.
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![Schematic representation of the experimental protocol used to evaluate the potential of ^68^Ga-Sienna+ for PET-guided MR imaging of sentinel lymph node biopsy.](ntnov03p0255g001){#SC1}

![Radiolabelling studies: (**a**) ^68^Ga-radiolabelling of Sienna+, (**b**) Radio-TLC of unchelated ^68^Ga and ^68^Ga-Sienna+; (**c**) Radiolabelling yield optimization at different pH and temperatures (mean ± SEM, n = 3-4); (**d**) Radiolabelling yields at 100 °C pH 6 using different reaction times (mean ± SEM, n = 3); (**e**) DLS measurement comparison of Sienna+ and ^68^Ga-Sienna+ (GMP protocol).](ntnov03p0255g002){#F1}

![*In vitro* experiments: (**a**) Stability of ^68^Ga-Sienna+ in human serum at 37 °C (mean ± SEM, n = 3). (**b**) Cell uptake of ^68^Ga-Sienna+ in breast cancer cells (3E.Δ.NT) and macrophages (J774A.1 and RAW264.7.GFP) at different time points (mean ± SEM, n = 3).](ntnov03p0255g003){#F2}

![*In vivo* imaging in the 3E.Δ.NT metastatic breast cancer model: (**a**) whole-body MIP SPECT-CT showing uptake of ^99m^TcO~4~^-^ in the primary tumour and left axillary lymph node (SLN~met~, filled arrowhead) due to metastasis, as well as uptake in NIS-expressing organs (thyroid/salivary glands and stomach); (**b**) coronal (top) and transversal (bottom) SPECT-CT images for the same mouse centered in SLN~met~ and showing presence of lung metastases; (**c**) coronal and transversal PET-CT images for the same mouse showing uptake of ^68^Ga-Sienna+ in SLN~health~ (open arrowhead), but not in SLN~met~. Note that, for clarity, the injection site and corresponding PET signal is not shown; (**d**) coronal and transversal MRI images (T2-weighted 3D turbo spin echo) of the same mouse showing the uptake of ^68^Ga-Sienna+ in SLN~health~, but not in SLN~met~ that appear bright and enlarged; (**e**) MIP PET-CT image showing the relative uptake of ^68^Ga-Sienna+ in brachial and axillary SLN~health~. Note that, for clarity, the injection site and corresponding PET signal is not shown; (**f**) Fluorescence photograph of same animal as in A-E showing the presence of metastasis in SLN~met~ but not in the contralateral area where SLN~health~ is located. All images are in right-left orientation; (**g**,**h**) ^68^Ga-Sienna+ uptake quantification (mean ± SEM) in SLN~met~ and SLN~health~ by (**g**) PET and (**h**) MRI.](ntnov03p0255g004){#F3}

![Histological analysis and PET-MRI coronal images of corresponding lymph nodes. Comparison of histology for fully metastatic (top row - with low macrophage density), metastatic (mid-row - medium macrophage density) and healthy lymph nodes (bottom row - high macrophage density) and corresponding MRI and PET-CT images where SLNs are marked with an arrow (SLN~met~: filled arrowhead; SLN~health~: open arrowhead). PET signal from the injection site is marked with an asterisk. Cancer cells (GFP stain) and macrophages (Iba1 stain) stain dark brown, iron (Pearls stain) in blue. Note weak non-specific GFP staining in SLN~health~ to non-cancer cells. Scale bars represent 100 µm.](ntnov03p0255g005){#F4}

###### 

Hydrodynamic size (HDS) and zeta potential measurements (mean ± SD) (n = 3)

  -------------------------------------------------------------------------------------
  Sample                              HDS (nm)\   HDS (nm)\            Zeta\
                                      Z-average   Intensity-weighted   potential (mV)
  ----------------------------------- ----------- -------------------- ----------------
  **Sienna+**                         59 ± 0.7    74 ± 32              -18 ± 3.4

  **^68^Ga-Sienna+** (GMP protocol)   57 ± 0.4    71 ± 32              -17 ± 1.2

  **^68^Ga-Sienna+** (small scale)    71 ± 0.6    94 ± 48              -11 ± 2.1
  -------------------------------------------------------------------------------------
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